Oklo stock got a fresh jolt on July 9, 2026, after 24/7 Wall St. set a 12-month target of $98.56, almost exactly double the day’s trading price of $49.27. The call implies 100.03% upside, a sharp reminder that Wall St still sees a wide gap between where the shares trade and where the bullish case says they could go.
That gap matters because the stock has already been through a violent reset. Oklo peaked at $193.84 in October 2025, then slid to a 52-week low of $44.88. By July 9, shares were still down 31.34% year to date and 12.77% over the past month, even as the company’s market value sat near $8.3 billion.
The new target is landing now because Oklo is trying to turn regulatory steps into a commercial story. On July 1, the DOE approved the Documented Safety Analysis for the Groves Isotope Test Reactor, and the project was targeting first criticality in July 2026. The company also has a 14 GW customer pipeline, a binding 1.2 gigawatt Meta agreement in Ohio, a Centrus Energy HALEU LOI and the acquisition of Creative Engineers behind it.
That is the case bulls are buying: regulatory momentum, customer interest and a power market that could be reshaped by AI demand. It is also why the stock drew attention on July 9 after a $67 million institutional bullish options bet was covered by CNBC. The bull scenario in the coverage points to $170.23, or a 245.49% return, if the company keeps converting promises into operating progress.
But the numbers underneath the story are still those of a pre-revenue company. Oklo reported a FY2024 net loss of $73.62 million, and Guggenheim initiated coverage in June with a Hold rating and a $54.06 target, while projecting EBITDA positive only by 2030. Reported losses were inflated by roughly $12.5 million in stock-based compensation, and research and development spending nearly tripled year over year, which shows how much cash is still being pushed into a business that has not yet reached commercial scale.
That is the friction inside the bullish setup: the approvals are real, but they are not revenue. The DOE step helps, and the customer pipeline sounds large, yet the next test is whether further NRC approvals, first criticality for the Groves Isotope Test Reactor and the Aurora program at Idaho National Laboratory in late 2027 can turn a story stock into a business with sales. Until that happens, Oklo remains a bet on execution, not proof of it.
